Literature DB >> 1466466

Reaction of sevoflurane and its degradation products with soda lime. Toxicity of the byproducts.

M Morio1, K Fujii, N Satoh, M Imai, U Kawakami, T Mizuno, Y Kawai, Y Ogasawara, T Tamura, A Negishi.   

Abstract

Sevoflurane previously has been reported to undergo extensive degradation in the presence of soda lime. To more completely characterize the extent and significnce of this reaction, we studied degradation of sevoflurane with and without soda lime, as well as the toxicity and mutagenicity of the degradation products. Two degradation products detected were CF2 = C(CF3)OCH2F (compound A) and CH3OCF2CH(CF3)OCH2F (compound B). During circulation of 1%, 2%, and 3% sevoflurance in a closed anesthesia circuit for 8 h, peak concentrations of compound A were 13.3 +/- 0.27, 30.2 +/- 0.10, and 42.1 +/- 1.07 ppm at 2 h, respectively. The concentrations of compound B did not exceed 2 ppm. The temperature of the soda lime was 43.3 +/- 2.8 degrees C at 1 h and increased gradually to 47.9 +/- 1.5 degrees C after 8 h. In closed flasks with soda lime, the magnitude of the decrease in sevoflurance concentrations (3%) and of the increase in compound A concentrations was temperature dependent. The peak concentrations of compound A at 23 degrees C, 37 degrees C, and 54 degrees C were 32.8 +/- 6.8 at 2 h, 46.6 +/- 1.0 at 0.5 h, and 78.5 +/- 2.3 ppm at 0.5 h, respectively. The LC50 (50% lethal concentration) of compound A in Wistar rats was 1,090 ppm in males and 1,050 ppm in females exposed for 1 h. The LC50 was 420 ppm in males and 400 ppm in females exposed for 3 h. The chronic toxicity of compound A in Wistar rats was studied by exposing rats 24 times, for 3 h each, to initial concentrations of 30, 60, or 120 ppm in a ventilated chamber. At all concentrations, there were no apparent effects other than a loss of body weight in females (120 ppm) on the final day (P < 0.01). Compound A did not induce mutation on the reverse (Ames) test at less than 2,500 micrograms/dish (culture medium 2.7 ml) with activation by S-9 mixture, and below 1,250 micrograms/dish (culture medium 2.7 ml) without activation, in four strains of S. typhimurium and in 1 strain of E. coli. Exposure of fibroblasts to 7,500 ppm of compound A for 1 h, compound A did not induce structural change. In a study of acute toxicity of compound B, there was no toxicity in Wistar rats after 3 h of exposure at 2,400 ppm. The reverse (Ames) test for compound B was negative at 625-1,250 micrograms/dish.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1466466     DOI: 10.1097/00000542-199212000-00017

Source DB:  PubMed          Journal:  Anesthesiology        ISSN: 0003-3022            Impact factor:   7.892


  25 in total

Review 1.  Safety considerations in the use of drug combinations during general anaesthesia.

Authors:  E S Ransom; R A Mueller
Journal:  Drug Saf       Date:  1997-02       Impact factor: 5.606

2.  RE: Yuge O: Renal toxicity of compound A with sevoflurane anesthesia: the benefits of sevoflurane appear to outweight the risks (editorial).J. Anesth 11:1-2.

Authors:  Edmond I Eger; Jackie L Martin
Journal:  J Anesth       Date:  1997-12       Impact factor: 2.078

3.  Renal toxicity of compound A with sevoflurane anesthesia: The benefits of sevoflurane appear to outweigh the risks.

Authors:  Osafumi Yuge
Journal:  J Anesth       Date:  1997-03       Impact factor: 2.078

4.  Carbon dioxide absorbents: does it matter which one you use?

Authors:  Jeffrey M Feldman
Journal:  J Clin Monit Comput       Date:  2018-01-10       Impact factor: 2.502

5.  Compound A concentration and the temperature of CO2 absorbents during low-flow sevoflurane anesthesia in surgical patients.

Authors:  M Osawa; T Shinomura; M Murakawa; K Mori
Journal:  J Anesth       Date:  1995-03       Impact factor: 2.078

6.  Urinary sevoflurane and hexafluoro-isopropanol as biomarkers of low-level occupational exposure to sevoflurane.

Authors:  Antonio Accorsi; Barbara Morrone; Irene Domenichini; Simona Valenti; Giovanni Battista Raffi; Francesco Saverio Violante
Journal:  Int Arch Occup Environ Health       Date:  2005-04-30       Impact factor: 3.015

7.  Comparison between low flow sevoflurane anesthesia and total intravenous anesthesia during intermediate-duration surgery: effects on renal and hepatic toxicity.

Authors:  S H Sahin; S O Cinar; I Paksoy; N Sut; S Oba
Journal:  Hippokratia       Date:  2011-01       Impact factor: 0.471

8.  Effect of sevoflurane anesthesia on the severity of renal histopathologic changes in rabbits pretreated with gentamicin: A controlled, investigator-blinded, experimental study.

Authors:  Azize Bestas; Mustafa Kemal Bayar; Nusret Akpolat; Mehmet Nihat Okuducu
Journal:  Curr Ther Res Clin Exp       Date:  2006-11

9.  Comparison of Effects of Low-Flow Sevoflurane and Low-Flow Desflurane Anaesthesia on Renal Functions Using Cystatin C.

Authors:  Gökçen Duymaz; Seyhan Yağar; Ayşegül Özgök
Journal:  Turk J Anaesthesiol Reanim       Date:  2017-04-01

Review 10.  Clinical pharmacokinetics of sevoflurane.

Authors:  M Behne; H J Wilke; S Harder
Journal:  Clin Pharmacokinet       Date:  1999-01       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.